These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25152781)

  • 1. The Portuguese generic medicines market: a policy analysis.
    Simoens S
    Pharm Pract (Granada); 2009 Apr; 7(2):74-80. PubMed ID: 25152781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing competitive and sustainable Polish generic medicines market.
    Simoens S
    Croat Med J; 2009 Oct; 50(5):440-8. PubMed ID: 19839067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto AG; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):345-53. PubMed ID: 24758569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of French generic medicines retail market: why the use of generic medicines is limited.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):795-803. PubMed ID: 25095903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encouraging the use of generic medicines: implications for transition economies.
    King DR; Kanavos P
    Croat Med J; 2002 Aug; 43(4):462-9. PubMed ID: 12187525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical policy regarding generic drugs in Belgium.
    Simoens S; De Bruyn K; Bogaert M; Laekeman G
    Pharmacoeconomics; 2005; 23(8):755-66. PubMed ID: 16097838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses.
    Leopold C; Zhang F; Mantel-Teeuwisse AK; Vogler S; Valkova S; Ross-Degnan D; Wagner AK
    Int J Equity Health; 2014 Jul; 13():53. PubMed ID: 25062657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?
    Dylst P; Vulto A; Simoens S
    Pharm Pract (Granada); 2012 Jan; 10(1):3-8. PubMed ID: 24155810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicians' perception of generic and electronic prescribing: A descriptive study from Jordan.
    El-Dahiyat F; Kayyali R; Bidgood P
    J Pharm Policy Pract; 2014; 7():7. PubMed ID: 25848547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Portuguese generic medicines market: What's next?
    Nunes AM; Ferreira DC; de Matos A; Julião RM
    Health Policy; 2020 Apr; 124(4):397-403. PubMed ID: 32139170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pricing models for generic medicines to ensure long-term sustainable competition in Europe.
    Francois C; Gawlik G; Mestre-Ferrandiz J; Pana A; Perelman J; Yfantopoulos J; Simoens S
    Front Pharmacol; 2023; 14():1200641. PubMed ID: 37876734
    [No Abstract]   [Full Text] [Related]  

  • 17. Generics: keep a balanced view.
    Prescrire Int; 2014 Feb; 23(146):52-5. PubMed ID: 24669392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reference pricing system and competition: case study from Portugal.
    Portela C
    Croat Med J; 2009 Oct; 50(5):429-39. PubMed ID: 19839066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.